Advances in Hematology / 2010 / Article / Tab 2

Review Article

Impact of Autologous and Allogeneic Stem Cell Transplantation in Peripheral T-Cell Lymphomas

Table 2

Studies on high-dose therapy and autologous stem cell transplantation in PTCL as first-line therapy.
(a) Retrospective data

AuthorYear AgeHistologies (WHO)IPIHigh-dose regimenStatus at TxDFS/EFS/ PFS/RFSOSFollowup (months)Comment

Rodríguez et al. [38]20071946AITL 100%aaIPI
0/1   37%
2/3   63%
BEAM/BEAC (79%)CR1 42%
PR1 26%
55% (3 y)60% (3 y)2515/19 transplanted 1.line

Rodríguez et al. [39]20077446PTCLu 50%
ALCL 31%
AITL 11%
Other 7%
aaIPI
0/1   35%
2/3   65%
BEAM/BEAC (91%)No data63% (5 y)68% (5 y)67

Feyler et al. [40]20076445PTCLu 47%
ALCL 31%
AITL 8%
Other 14%
0/1   34%
2   11%
3   11%
4/5   2%
Unknown 42%
DiverseCR1 48%
PR1 23%
50% (3 y)53% (3 y)48Incl. CTCL, T-cell leukemia/lymphoma 46/64 transplanted 1.line

Kyriakou et al. [41]200814653AITL 100%No dataBEAM (74%)CR1 33%
PR 36%
49% (4 y)59% (4 y)31101/146 transplanted 1.line

Prochazka et al. [42]20091859PTCLu 56%
ALCL 39%
AITL 6%
0/1   28%
2   28%
≥3   44%
BEAMNo data52% (2 y)71% (2 y)26

Numata et al. [43]20103953PTCLu 31%
AITL 28%
ALCL 23%
NK/T 18%
aaIPI
0/1   33%
2/3   59%
Unknown 8%
MCEC ( )
TBI-based ( )
CR1 69%61% (5 y)62% (5 y)7823/39 transplanted 1.line

Studies including both patients receiving HDT-autoSCT 1.line and 2.line are listed in the table representing the predominant group.
(b) Prospective data

AuthorYear AgeHistologies (WHO)IPIHigh-dose regimenStatus at TxTx rateDFS/EFS/ PFSOSFollowup (months)Comment

Mounier et al. [44]20042836PTCLu 56%
Precursor 44%
0/1   25%
≥2   75%
BEAM/CBVCR 100%No data44% (5 y)54% (5 y)78′Incl. precursor T-cell lymphoma

Nickelsen et al. [45]20093348 39%
PTCLu 33%
AITL 12%
Other 16%
aaIPI
0/1   9%
2/3   91%
MegaCHOEPCR 49%
PR 6%
after therapy
67%26% (3 y)45% (3 y)53Sequential HDT-autoSCT Subgroup analysis

Corradini et al. [46]20066243PTCLu 45%
ALK+ ALCL 30%
AITL 16%
Other 9%
0/1   19%
≥2   71%
Mito/Mel or BEAMCR 56%
PR 16%
71%30% (12 y)34% (12 y)76Incl.

Rodríguez et al. [47]20072644PTCLu 42%
31%
AITL 27%
aaIPI
0/1   28%
2/3   72%
BEAMCR 65%
PR 8%
73%53% (3 y)73% (3 y)35’No 13/26 transplanted 1.line

Mercadal et al. [48]20084147PTCLu 49%
AITL 29%
HSTL 5%
NK/T 5%
Other 12%
0/1   22%
2   32%
3   22%
4/5   24%
BEAM/BEACCR 49%
PR 10%
41%30% (4 y)39% (4 y)38No

Reimer et al. [49]20098347PTCLu 39%
AITL 33%
16%
Other 12%
aaIPI
0/1   49%
2/3   51%
Cy/TBICR 47%
PR 24%
66%36% (3 y)48% (3 y)33No

D'Amore et al. [50]200916057PTCLu 39%
AITL 19%
19%
HSTL 13%
Other 10%
0/1   18%
≥2   72%
BEAMNo data71%49% (3 y)57% (3 y)45No